Showing results (241-250 of 329) with videos related to
Sort By:
Pageof 33
European Heart Journal|May 4, 2015
Effect of genetic variations on ticagrelor plasma levels and clinical outcomesChristoph Varenhorst, Niclas Eriksson, Åsa Johansson, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 16, 2014
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI studyThomas J Povsic, John P Vavalle, John H Alexander, et al.Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.Pharmacogenomics|April 3, 2012
CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjectsMark Y Chan, Karen Tan, Huay-Cheem Tan, et al.European Heart Journal|November 18, 2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trialRichard C Becker, Jean Pierre Bassand, Andrzej Budaj, et al.American Heart Journal|June 15, 2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) TrialYuichi J Shimada, Sameer Bansilal, Stephen D Wiviott, et al.The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.Journal of the American College of Cardiology|November 28, 2015
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF TrialMatthew W Sherwood, Christopher C Nessel, Anne S Hellkamp, et al.Pageof 33